ERADIVIR, INC.

Biotech · Private

Small molecule therapeutic conjugate that binds coronavirus and triggers immune response

Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: A therapeutic molecule for COVID-19$256,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1623NOVALEX THERAPEUTICS, INC.——
1624RADIKAL THERAPEUTICS, INC.——
1625Chan Zuckerberg Biohub——
1626ERADIVIR, INC.——
1627Sarkar-Klein-Labs——
1628Wildflower Biopharma Inc——
1629KIROMIC BIOPHARMA INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Conjugates, Compositions And Methods For Treating Rsv Infectionapplication
  • Conjugates, Compositions And Methods For Treating Influenzaapplication
  • Fc FRAGMENTS, CONJUGATES, COMPOSITIONS, AND METHODS OF USEapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.